drugset
drugset / Trial / NCT04228406

Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy Evaluation of GST-HG161

NCT04228406 ↗

Phase 1 Unknown 62 enrolled Fujian Cosunter Pharmaceutical Co. Ltd
NaSingle-groupOpen-labelTreatment

Summary

Safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy evaluation of the selective c-MET inhibitor GST-HG161 in patients with advanced or metastatic solid tumors: An open, single and multiple administration, dose escalation, and expanded phase I trial

Timeline

Start
2019-07-01
Primary completion
2020-09-30
Completion
2020-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject GST-HG161 Unknown 60 mg Oral
Subject GST-HG161 Unknown 150 mg Oral
Subject GST-HG161 Unknown 300 mg Oral
Subject GST-HG161 Unknown 450 mg Oral
Subject GST-HG161 Unknown 600 mg Oral
Subject GST-HG161 Unknown 750 mg Oral
Subject GST-HG161 Unknown 900 mg Oral

Indications

neoplasm